Liljenquist (born July 10, 1974) is an American businessman and former politician.
Dan is the lead architect and Board Chair of Civica Rx, a nonprofit generic drug company established in 2018 to reduce chronic generic drug shortages and price gouging, which have negatively impacted patient care for over a decade.
Dan’s commentary on generic drug market issues was published in the New England Journal of Medicine (Addressing Generic Drug Market Failures—The Case for Establishing a Nonprofit Manufacturer) and informed Civica Rx’s mission to ensure that essential generic medications are available and affordable to everyone.
Dan is Senior Vice President and Chief Strategy Officer for Intermountain Healthcare, where he also oversees Intermountain’s Enterprise Initiative and Market Intelligence & Planning Offices.
Prior to joining Intermountain, Dan served in the Utah State Senate and was nationally recognized for his work on Medicaid and public-sector pension reforms.
He was a Republican member of the Utah State Senate representing the state's 23rd senate district in Davis County from January 2009 to December 2011.
He resigned to run in the 2012 election for U.S.
Senate against 36-year-incumbent United States Senator Orrin Hatch.
Liljenquist was defeated by Hatch in the primary election.
He is a former strategy consultant with Bain & Company, Inc.
In addition to his role as Chair of the Civica Rx Board, he serves on multiple non-profit boards, including the Lucy Burns Institute, which publishes Ballotpedia.